When it comes to understanding the science of memory, no
detail is too small. To learn more, watch our LinkedIn Live
stream on the real-world implications of study design
methods and data evaluation in Alzheimer’s disease clinical research.
THE NEW AGE OF
ALZHEIMER’S DISEASE
A new age for Alzheimer’s disease (AD) stands before us, with
unprecedented possibilities for patients, care partners, and health
care professionals. Paired with our long-term vision and commitment
to our human health care (hhc) mission, we use deep human biology
and genetic evidence with the goal of providing the right
intervention, for the right person, at the right time.
WHAT IS ALZHEIMER’S DISEASE?
Alzheimer’s disease (AD) is progressive. Even in the early stages, AD can begin to interfere with daily life.
AD is linked to the build-up of amyloid protein in the brain, which over time can damage brain cells and clump together into harmful amyloid brain plaques.
Various mechanisms have been proposed over the years to describe the pathogenic events that lead to the development of AD, all of which suggest that the presence of Aβ and tau, synaptic failure, and neuronal dysfunction are common features of AD and play a pivotal role in cognitive dysfunction.
WHAT DOES ALZHEIMER’S LOOK LIKE?
There are many complexities in the AD landscape: risk factors, early symptoms,
causes, diagnoses, and stages. Early detection is one of the keys to the right person, receiving the right medication, at the right time.
THE KEY TO OUR PROGRESS IN TWO WORDS?
RESEARCH EXCELLENCE.
WHAT IS AD LIKE FOR PATIENTS?
"I WANT YOU TO SEE ME, NOT MY ALZHEIMER'S." A
PATIENT'S STORY BY PHOTOGRAPHER MARK TIMMONS.
Many people who are living with early-stage Alzheimer’s
disease may still be working, enjoying travel, and sharing
quality time with family.
Watch Mark’s video to hear about
his journey with AD. (Mark was compensated for his
participation in
this video.)
ASSESSING MEANINGFUL BENEFITS IN EARLY ALZHEIMER’S DISEASE (AD)
Click on the video on the right to
hear expert discussions on assessing meaningful benefits in early AD using a holistic approach that incorporates multiple stakeholder perspectives: view full series here
PATIENT-CENTERED CARE FRAMEWORK IN ALZHEIMER’S DISEASE (AD)
Click on the video on the right to
hear experts discuss the urgent need for a patient-centered framework in AD to ensure a timely diagnosis and appropriate patient identification. The time is now: view full series here
DIG DEEPER: RESOURCES FOR HCPS
PIPELINE
Learn about the therapies we are exploring.